Amphastar Pharmaceuticals (AMPH) Expected to Release Earnings on Thursday

Amphastar Pharmaceuticals (NASDAQ:AMPH) is projected to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of $0.66 per share and revenue of $179.9210 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.28). The firm had revenue of $171.17 million for the quarter, compared to analyst estimates of $173.46 million. Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. On average, analysts expect Amphastar Pharmaceuticals to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Amphastar Pharmaceuticals Stock Up 1.4%

Amphastar Pharmaceuticals stock opened at $20.22 on Tuesday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.82 and a current ratio of 3.85. Amphastar Pharmaceuticals has a one year low of $16.65 and a one year high of $31.26. The company has a 50-day simple moving average of $19.57 and a 200-day simple moving average of $21.54. The firm has a market capitalization of $891.50 million, a P/E ratio of 12.18, a P/E/G ratio of 4.21 and a beta of 0.89.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AMPH. Los Angeles Capital Management LLC lifted its holdings in Amphastar Pharmaceuticals by 2.4% in the 4th quarter. Los Angeles Capital Management LLC now owns 19,397 shares of the company’s stock worth $478,000 after purchasing an additional 459 shares during the last quarter. Advisory Research Inc. grew its holdings in Amphastar Pharmaceuticals by 3.8% during the third quarter. Advisory Research Inc. now owns 15,468 shares of the company’s stock valued at $412,000 after purchasing an additional 570 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Amphastar Pharmaceuticals by 2.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company’s stock valued at $652,000 after purchasing an additional 613 shares during the last quarter. Janney Montgomery Scott LLC raised its position in shares of Amphastar Pharmaceuticals by 6.2% in the fourth quarter. Janney Montgomery Scott LLC now owns 14,230 shares of the company’s stock valued at $381,000 after purchasing an additional 825 shares during the period. Finally, Commonwealth Equity Services LLC raised its position in shares of Amphastar Pharmaceuticals by 11.2% in the fourth quarter. Commonwealth Equity Services LLC now owns 8,742 shares of the company’s stock valued at $234,000 after purchasing an additional 882 shares during the period. 65.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on AMPH shares. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, May 8th. Barclays cut their price target on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a report on Wednesday, June 3rd. Zacks Research upgraded Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 21st. Jefferies Financial Group reissued a “hold” rating and issued a $22.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Finally, Wells Fargo & Company restated an “equal weight” rating and issued a $19.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a research report on Thursday, May 14th. Six research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $22.00.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.